GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test
GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test NEW YORK APRIL 15, 2021 — GBS, Inc. (GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute) have received approval from the Harvard Longwood campus […]
GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests
GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests New York, NY, February 18, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary health practitioners, today announced […]
Harvard’s Wyss Institute collaborates with GBS Inc. on the Wyss’ eRapid-based COVID-19 diagnostic to help curb the pandemic
Harvard’s Wyss Institute collaborates with GBS Inc. on the Wyss’ eRapid-based COVID-19 diagnostic to help curb the pandemic Combination of the Wyss’ electrochemical sensing technology with GBS’s transistor technology could enable fast, multiplexed, low-cost COVID-19 biomarker analysis in point-of-care applications This article has been republished with permission from the Wyss Institute at Harvard University. Click […]
FDA Engagement Commences for Saliva Glucose Biosensor in the US
FDA Engagement Commences for Saliva Glucose Biosensor in the US SYDNEY – May 6, 2020 The iQ Group Global is pleased to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) has commenced engagement with the US Food and Drug Administration (FDA) for the approval pathway of the Saliva Glucose Biosensor. On May 1st, LSBD […]
The iQ Group Global Partners with Harvard University for Real-Time, Printable COVID-19 Diagnostic Test
The iQ Group Global Partners with Harvard University for Real-Time, Printable COVID-19 Diagnostic Test SYDNEY – May 29, 2020 The iQ Group Global has announced a collaboration with Harvard University to develop a printable point-of-care SARS-CoV-2 antibody test for the COVID-19 disease that could produce results in real-time. Life Science Biosensor Diagnostics Pty Ltd (LSBD), […]
The iQ Group Global Introduces the Saliva Glucose Biosensor
The iQ Group Global Introduces the Saliva Glucose Biosensor The world’s first non-invasive, saliva-based glucose test for diabetes management SYDNEY – February , 2019 – The iQ Group Global, a consortium of life science and financial services companies which span the biopharma value chain from asset discovery to commercialization, today introduced the Saliva Glucose Biosensor. […]